Senseonics (NYSEAMERICAN:SENS) announced its quarterly earnings data on Tuesday. The company reported ($0.12) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.01, Briefing.com reports. The business had revenue of $2.90 million during the quarter, compared to analyst estimates of $2.95 million. Senseonics had a negative net margin of 828.76% and a negative return on equity of 406.72%. The business’s quarterly revenue was up 866.7% compared to the same quarter last year.
Shares of Senseonics (NYSEAMERICAN SENS) traded up $0.15 on Wednesday, hitting $3.22. 518,694 shares of the stock were exchanged, compared to its average volume of 491,711. The firm has a market capitalization of $413.30 and a price-to-earnings ratio of -6.14. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.93 and a quick ratio of 2.81. Senseonics has a 1-year low of $1.26 and a 1-year high of $3.67.
Separately, Canaccord Genuity reaffirmed a “buy” rating on shares of Senseonics in a research report on Friday, March 2nd.
Senseonics Holdings, Inc is a medical technology company. The Company focuses on the design, development and commercialization of glucose monitoring systems. The Company operates through glucose monitoring systems segment. It offers a continuous glucose monitoring (CGM) system, Eversense, which is designed an implantable CGM system designed to continually measure glucose levels in people with diabetes.
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.